Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus

Summit Therapeutics SMMT reported fourth-quarter 2025 loss per share of 29 cents, wider than the Zacks Consensus Estimate of 22 cents. In the year-ago period, the company had incurred a loss of 8